This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Leukemia Open Access 29 April 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kaushansky K . The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54-year-old speculation comes of age. Best Pract Res Clin Haematol 2007; 20: 5–12.
Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M et al. The JAK2V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. PNAS 2006; 103: 6224–6229.
Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472–3476.
Scott LM, Tong W, Levine M, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. NEJM 2007; 356: 459–468.
Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A . Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; Epub ahead of print (June 28): 1–4.
Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organisation diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097.
Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N . The JAK2V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. BJH 2007; 136: 745–751.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Butcher, C., Hahn, U., To, L. et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 22, 870–873 (2008). https://doi.org/10.1038/sj.leu.2404971
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404971
This article is cited by
-
JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis
Annals of Hematology (2020)
-
Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera
Journal of Hematopathology (2020)
-
Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring
Annals of Hematology (2015)
-
JAK2 V617F, MPL W515L and JAK2 exon 12 mutations in Chinese patients with primary myelofibrosis
Chinese Journal of Cancer Research (2012)
-
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Leukemia (2010)